Free Trial
→ Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX (From InvestorPlace) (Ad)tc pixel Free TLPPF Stock Alerts

Telix Pharmaceuticals (TLPPF) Financials

Telix Pharmaceuticals logo
$10.50 0.00 (0.00%)
As of 05/5/2026
Compare
Annual Income Statements for Telix Pharmaceuticals

Annual Income Statements for Telix Pharmaceuticals

This table shows Telix Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -71 7.80 64 -15
Consolidated Net Income / (Loss)		 -71 7.80 64 -15
Net Income / (Loss) Continuing Operations		 -68 7.80 64 -15
Total Pre-Tax Income 		-67 1.98 35 -6.51
Total Operating Income		 -63 2.59 38 -5.27
Total Gross Profit		 65 210 336 426
Total Revenue		 109 310 529 821
Operating Revenue		 109 334 524 810
Other Revenue		 - -24 4.89 12
Total Cost of Revenue		 44 139 222 463
Operating Cost of Revenue		 44 139 222 463
Total Operating Expenses		 112 168 269 364
Selling, General & Admin Expense		 32 50 85 96
Marketing Expense		 25 33 56 97
Research & Development Expense		 55 85 128 171
Total Other Income / (Expense), net		 -17 -0.61 -3.29 -1.24
Interest & Investment Income		 0.00 -0.61 -3.29 -1.24
Income Tax Expense		 3.71 -1.61 4.23 1.86
Other Gains / (Losses), net		 - 4.21 34 -7.13
Weighted Average Basic Shares Outstanding		 - - 334.72M 338.78M
Weighted Average Diluted Shares Outstanding		 - - 334.72M 338.78M
Weighted Average Basic & Diluted Shares Outstanding		 - - 334.72M 338.78M

Quarterly Income Statements for Telix Pharmaceuticals

No quarterly income statements for Telix Pharmaceuticals are available.

Annual Cash Flow Statements for Telix Pharmaceuticals

This table details how cash moves in and out of Telix Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 81 -599 358 -307
Net Cash From Operating Activities		 -16 -596 27 -17
Net Cash From Continuing Operating Activities		 -16 -596 2.06 -29
Net Income / (Loss) Continuing Operations		 0.00 -312 0.00 0.00
Changes in Operating Assets and Liabilities, net		 - 4.49 2.06 -29
Net Cash From Investing Activities		 84 -6.31 -87 -286
Net Cash From Continuing Investing Activities		 84 -6.31 -84 -278
Purchase of Property, Plant & Equipment		 - -6.31 -22 -44
Acquisitions		 - 0.00 -21 -221
Purchase of Investments		 - - -41 -13
Net Cash From Financing Activities		 13 4.19 417 -3.72
Net Cash From Continuing Financing Activities		 13 4.19 417 -3.72
Repayment of Debt		 - 0.00 -2.06 -6.06
Issuance of Debt		 - 4.19 418 0.53
Other Financing Activities, net		 13 - 0.66 1.81

Quarterly Cash Flow Statements for Telix Pharmaceuticals

No quarterly cash flow statements for Telix Pharmaceuticals are available.

Annual Balance Sheets for Telix Pharmaceuticals

This table presents Telix Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 277 940 1,164
Total Current Assets		 159 570 330
Cash & Equivalents		 84 440 142
Accounts Receivable		 44 87 129
Inventories, net		 13 24 37
Current Deferred & Refundable Income Taxes		 5.24 5.91 6.04
Other Current Assets		 12 14 16
Plant, Property, & Equipment, net		 16 28 59
Plant, Property & Equipment, gross		 16 28 59
Total Noncurrent Assets		 103 342 775
Long-Term Investments		 8.39 35 37
Intangible Assets		 75 258 593
Noncurrent Deferred & Refundable Income Taxes		 14 29 59
Other Noncurrent Operating Assets		 5.29 21 86
Total Liabilities & Shareholders' Equity		 246 838 1,134
Total Liabilities		 175 587 749
Total Current Liabilities		 111 205 232
Short-Term Debt		 0.66 12 13
Accounts Payable		 54 87 150
Current Deferred & Payable Income Tax Liabilities		 13 30 31
Other Current Liabilities		 8.32 9.09 6.51
Total Noncurrent Liabilities		 63 382 517
Long-Term Debt		 5.95 342 392
Capital Lease Obligations		 5.25 5.04 57
Noncurrent Deferred & Payable Income Tax Liabilities		 0.00 5.80 45
Other Noncurrent Operating Liabilities		 14 11 13
Total Equity & Noncontrolling Interests		 103 353 415
Total Preferred & Common Equity		 144 337 427
Total Common Equity		 144 337 427
Common Stock		 315 414 480
Retained Earnings		 -187 -153 -155
Other Equity Adjustments		 16 76 102

Quarterly Balance Sheets for Telix Pharmaceuticals

No quarterly balance sheets for Telix Pharmaceuticals are available.

Annual Metrics And Ratios for Telix Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Telix Pharmaceuticals' official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - -
Revenue Growth		 0.00% 193.13% 51.69% 55.38%
EBITDA Growth		 0.00% 102.64% 2,709.41% -113.89%
EBIT Growth		 0.00% 102.64% 2,709.41% -113.89%
NOPAT Growth		 0.00% 107.66% 1,248.70% -111.08%
Net Income Growth		 0.00% 105.02% 767.74% -124.17%
EPS Growth		 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 0.00% -1,631.30% 109.55% -162.91%
Free Cash Flow Firm Growth		 0.00% 0.00% -102.39% -115.58%
Invested Capital Growth		 0.00% 0.00% 243.41% 128.89%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - -
Gross Margin		 59.29% 67.22% 65.08% 51.92%
EBITDA Margin		 -69.13% 0.62% 11.52% -0.64%
Operating Margin		 -57.42% 0.62% 10.49% -0.64%
EBIT Margin		 -69.13% 0.62% 11.52% -0.64%
Profit (Net Income) Margin		 -65.01% 1.11% 6.37% -1.89%
Tax Burden Percent		 105.53% 168.80% 89.05% 238.05%
Interest Burden Percent		 89.10% 106.08% 62.11% 123.59%
Effective Tax Rate		 0.00% -68.80% 10.95% 0.00%
Return on Invested Capital (ROIC)		 0.00% 7.16% 21.77% -0.69%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 2.03% 98.27% -8.70%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -0.16% -8.14% -3.34%
Return on Equity (ROE)		 0.00% 7.00% 13.63% -4.03%
Cash Return on Invested Capital (CROIC)		 0.00% -192.84% -88.02% -79.07%
Operating Return on Assets (OROA)		 0.00% 0.72% 9.19% -0.50%
Return on Assets (ROA)		 0.00% 1.28% 5.08% -1.47%
Return on Common Equity (ROCE)		 0.00% 9.95% 14.44% -4.01%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 2.46% 9.20% 0.00%
Net Operating Profit after Tax (NOPAT)		 -44 3.35 45 -3.69
NOPAT Margin		 -40.20% 1.05% 9.34% -0.45%
Net Nonoperating Expense Percent (NNEP)		 0.00% 5.13% -76.50% 8.00%
Return On Investment Capital (ROIC_SIMPLE)		 - 2.96% 6.38% -0.42%
Cost of Revenue to Revenue		 40.71% 44.28% 34.92% 56.35%
SG&A Expenses to Revenue		 29.45% 15.86% 16.58% 11.66%
R&D to Revenue		 50.40% 27.48% 24.85% 20.85%
Operating Expenses to Revenue		 102.54% 55.09% 52.34% 44.29%
Earnings before Interest and Taxes (EBIT)		 -75 1.99 56 -5.27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -75 1.99 56 -5.27
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 1.40 15.36 5.94
Price to Tangible Book Value (P/TBV)		 0.00 2.90 65.97 0.00
Price to Revenue (P/Rev)		 1.85 0.63 10.64 3.09
Price to Earnings (P/E)		 0.00 71.40 166.96 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 1.40% 0.60% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 1.29 15.66 3.81
Enterprise Value to Revenue (EV/Rev)		 0.00 0.38 10.40 3.43
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 60.79 90.27 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 60.79 90.27 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 36.01 111.39 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 189.33 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.00 0.11 1.02 1.11
Long-Term Debt to Equity		 0.00 0.11 0.99 1.08
Financial Leverage		 0.00 -0.08 -0.08 0.38
Leverage Ratio		 0.00 2.73 2.68 2.74
Compound Leverage Factor		 0.00 2.89 1.67 3.38
Debt to Total Capital		 0.00% 10.17% 50.47% 52.63%
Short-Term Debt to Total Capital		 0.00% 0.58% 1.66% 1.50%
Long-Term Debt to Total Capital		 0.00% 9.58% 48.81% 51.14%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 127.74% 47.29% 48.69%
Debt to EBITDA		 0.00 5.79 6.41 -87.65
Net Debt to EBITDA		 0.00 -40.77 -2.08 -53.66
Long-Term Debt to EBITDA		 0.00 5.46 6.20 -85.16
Debt to NOPAT		 0.00 3.43 7.92 -125.21
Net Debt to NOPAT		 0.00 -24.15 -2.56 -76.66
Long-Term Debt to NOPAT		 0.00 3.23 7.66 -121.66
Altman Z-Score		 0.00 1.16 6.26 2.64
Noncontrolling Interest Sharing Ratio		 0.00% -42.19% -5.95% 0.56%
Liquidity Ratios		 - - - -
Current Ratio		 0.00 1.41 2.78 1.43
Quick Ratio		 0.00 1.14 2.57 1.17
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -90 -183 -420
Operating Cash Flow to CapEx		 0.00% 0.00% 126.44% -39.50%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -8.01 0.00
Operating Cash Flow to Interest Expense		 -3.53 0.00 1.17 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -3.53 0.00 0.24 0.00
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 1.15 0.80 0.78
Accounts Receivable Turnover		 0.00 7.22 7.43 7.60
Inventory Turnover		 0.00 11.97 9.56 15.25
Fixed Asset Turnover		 0.00 20.19 22.21 18.99
Accounts Payable Turnover		 0.00 2.54 2.38 3.90
Days Sales Outstanding (DSO)		 0.00 50.55 49.16 48.02
Days Inventory Outstanding (DIO)		 0.00 30.50 38.20 23.94
Days Payable Outstanding (DPO)		 0.00 143.98 153.54 93.51
Cash Conversion Cycle (CCC)		 0.00 -62.93 -66.18 -21.55
Capital & Investment Metrics		 - - - -
Invested Capital		 0.00 94 322 740
Invested Capital Turnover		 0.00 6.82 2.33 1.54
Increase / (Decrease) in Invested Capital		 0.00 94 228 417
Enterprise Value (EV)		 0.00 121 5,039 2,820
Market Capitalization		 202 202 5,155 2,537
Book Value per Share		 $0.00 $8.50 $1.00 $1.28
Tangible Book Value per Share		 $0.00 $4.10 $0.23 ($0.50)
Total Capital		 0.00 113 710 877
Total Debt		 0.00 12 358 462
Total Long-Term Debt		 0.00 11 346 448
Net Debt		 0.00 -81 -116 283
Capital Expenditures (CapEx)		 0.00 0.00 21 44
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -37 -64 -30
Debt-free Net Working Capital (DFNWC)		 0.00 47 375 112
Net Working Capital (NWC)		 0.00 46 363 99
Net Nonoperating Expense (NNE)		 27 -0.20 14 12
Net Nonoperating Obligations (NNO)		 0.00 -7.96 -30 325
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -11.72% -13.24% -3.66%
Debt-free Net Working Capital to Revenue		 0.00% 14.63% 77.46% 13.61%
Net Working Capital to Revenue		 0.00% 14.42% 75.03% 12.01%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $9.32 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 334.72M 338.78M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $8.94 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 334.72M 338.78M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 334.72M 338.78M
Normalized Net Operating Profit after Tax (NOPAT)		 -44 1.39 45 -3.69
Normalized NOPAT Margin		 -40.20% 0.44% 9.34% -0.45%
Pre Tax Income Margin		 -61.60% 0.66% 7.16% -0.79%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 -16.54 0.00 2.44 0.00
NOPAT to Interest Expense		 -9.61 0.00 1.98 0.00
EBIT Less CapEx to Interest Expense		 -16.54 0.00 1.52 0.00
NOPAT Less CapEx to Interest Expense		 -9.61 0.00 1.06 0.00
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Telix Pharmaceuticals

No quarterly metrics and ratios for Telix Pharmaceuticals are available.


Financials Breakdown Chart

Frequently Asked Questions About Telix Pharmaceuticals' Financials

When does Telix Pharmaceuticals' fiscal year end?

According to the most recent income statement we have on file, Telix Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Telix Pharmaceuticals' net income changed over the last 3 years?

Telix Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$15.49 million in 2025, falling from -$70.83 million in 2022. The previous period was $64.08 million in 2024.

What is Telix Pharmaceuticals' operating income?
Telix Pharmaceuticals' total operating income in 2025 was -$5.27 million, based on the following breakdown:
  • Total Gross Profit: $426.44 million
  • Total Operating Expenses: $363.80 million
How has Telix Pharmaceuticals' revenue changed over the last 3 years?

Over the last 3 years, Telix Pharmaceuticals' total revenue changed from $108.95 million in 2022 to $821.36 million in 2025, a change of 653.9%.

How much debt does Telix Pharmaceuticals have?

Telix Pharmaceuticals' total liabilities were at $748.61 million at the end of 2025, a 27.4% increase from 2024, and a 328.7% increase since 2023.

How much cash does Telix Pharmaceuticals have?

In the past 2 years, Telix Pharmaceuticals' cash and equivalents has ranged from $84.30 million in 2023 to $440.00 million in 2024, and is currently $141.87 million as of their latest financial filing in 2025.

How has Telix Pharmaceuticals' book value per share changed over the last 3 years?

Over the last 3 years, Telix Pharmaceuticals' book value per share changed from 0.00 in 2022 to 1.28 in 2025, a change of 127.6%.



Financial statements for OTCMKTS:TLPPF last updated on 2/22/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Bigger than SpaceX, Tesla, xAI combined?!
The Wall Street legend who recommended Tesla in 2012 before its 16,724% move reveals... Musk's 2026 Project...
The Oxford Club | Sponsoredtc pixel
Get Ahead of Asia's Market Wave U.S. Solar Growth with PMAX.
Powell Max Limited (NASDAQ: PMAX) operates at the center of Hong Kong's $4.5 trillion capital markets, providi...
Smallcaps Daily | Sponsoredtc pixel
This AI stat will shock you …
AI stocks may be more overhyped than most investors realize - and one data point is making that case hard to i...
Weiss Ratings | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
When the PC replaced the mainframe, companies that missed the shift went bankrupt. George Gilder - who called ...
Eagle Publishing | Sponsoredtc pixel
How to collect $1,170/month from silver
There is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...
Investors Alley | Sponsoredtc pixel